Skip to main content

Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain Tumor

Trial Status: Enrolling by Invitation

Background: Psychological distress affects many people diagnosed with a primary malignant brain tumor (PBT). Distress can include negative feelings such as anger, fear, or sadness. Researchers want to see if a type of therapy called CALM can help. It promotes well-being in people who have cancer that cannot be cured. Objective: To find out if the CALM therapy can help people with a PBT suffering from distress. Eligibility: English-speaking adults ages 18 and older who have a PBT and are taking part in NIH protocol #16C0151. Design: This study will not take place in person. It will be done by smartphone, computer, or tablet. Participants will fill out 7 surveys. The surveys will take 40 to 60 minutes to complete. They are all electronic. They will ask about physical and emotional symptoms, depression, feelings about death and dying, feelings about close relationships, and general well-being. Participants will be assigned to a CALM therapist. They will have 3 to 6 individual therapy sessions in 6 months. Each session will last 45 to 60 minutes. Sessions may be audio recorded. If needed, participants may have extra sessions. CALM includes symptom management and discussions of meaning, purpose, and mortality. Participants may have a family member take part in at least one CALM session with them. After the third CALM session, participants will be asked questions about CALM. After 3 and 6 months, participants will complete the 7 surveys again. Participation will last about 6 months.

Inclusion Criteria

  • - INCLUSION CRITERIA: - Subjects with histological or imaging confirmation of PBT who are undergoing standard of care or experimental treatment. - Adults (greater than or equal to 18 years of age) who are English-speaking - Subjects who have a life expectancy of at least 3 months from time of study entry to allow for participation in the 3 required sessions. - Subjects must be enrolled on the Neuro-Oncology Branch Natural History Study 16C0151. - The ability of the subject to understand and the willingness to sign a written informed consent document as determined by the assessment of the treating physicians. EXCLUSION CRITERIA: -Participants without access to a smartphone, computer, or tablet to complete remote sessions.

Maryland

Bethesda
National Institutes of Health Clinical Center
Status: ENROLLING_BY_INVITATION

PRECIS

Background:

Psychological distress is an emotional state experienced by primary brain tumor (PBT)

patients throughout the illness trajectory. It can often be under identified in this patient

population.

Limited therapeutic interventions in managing distress symptoms can allow symptoms to linger

without tailored mechanisms to manage the emotional challenges experienced with a tumor

diagnosis. Individualized therapy in advanced cancer patients is a preferred method over

pharmacological interventions when managing psychological distress, but more evidence-based

research is needed to address the benefits.

The CALM intervention is a brief, individualized psychotherapeutic intervention established

to meet an unmet need to address psychological distress and promote well-being in advanced

cancer patients. Previous studies implementing the CALM intervention have focused on

metastatic and advanced cancer patients and have reported positive effects. Implementing the

CALM intervention in a sample of PBT patients will be one of the first studies to identify

the preliminary effectiveness.

Objective:

To demonstrate the effects of the CALM intervention in reduction of depressive symptoms using

the PROMIS-Depression scale in PBT participants, from baseline to 6 months.

Eligibility:

Adult participants greater than or equal to 18 years of age with a PBT diagnosis who are

undergoing standard of care or experimental treatment.

- The ability of the subject to speak English

- Subjects who have a life expectancy of at least 3 months from time of study entry to

allow for participation in the 3 required sessions.

- The ability of the subject to understand and willing to sign a written informed consent

document as determined by the assessment of the clinical team.

Design:

A total of 100 participants will be enrolled

Neuro-Oncology participants being seen in the clinical center or receiving telehealth

services will be screened to participate. Participants will be assigned a CALM therapist and

all sessions will be completed remotely.

Data from standardized measures will be collected at 3 timepoints (Baseline, 3 months, 6

months) and qualitative interviews will be completed after the 3rd CALM session.

Approximate time for sessions is 45-60 minutes.

Trial Phase Phase NA

Trial Type Treatment

Lead Organization
National Cancer Institute

Principal Investigator
Terri Sue Armstrong

  • Primary ID 10000293
  • Secondary IDs NCI-2021-03771, 000293-C
  • Clinicaltrials.gov ID NCT04852302